Showing results (191-200 of 222) with videos related to

Sort By:
Pageof 23
Therapeutic Advances in Medical Oncology|April 22, 2020
Inhibition of the Wnt/β-catenin pathway enhances antitumor immunity in ovarian cancerDavid W Doo, Selene Meza-Perez, Angelina I Londoño, et al.
Cancer Research Communications|November 26, 2024
Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian CancerMaj K Kjeldsen, Morten Jørgensen, Dina Sofie B Grønseth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 11, 2020
Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, et al.
Molecular Cancer Therapeutics|August 28, 2020
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.
International Journal of Cancer|December 10, 2008
Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong womenTony K H Chung, Tak-Hong Cheung, Ngar-Yee Huen, et al.
Plos One|May 3, 2011
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancersÅslaug Helland, Michael S Anglesio, Joshy George, et al.
The New England Journal of Medicine|December 19, 2008
Dicer, Drosha, and outcomes in patients with ovarian cancerWilliam M Merritt, Yvonne G Lin, Liz Y Han, et al.
Cancer Research|January 28, 2012
Ovarian cancer risk associated with inherited inflammation-related variantsKristin L White, Joellen M Schildkraut, Rachel T Palmieri, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 14, 2019
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian CancerAmit M Oza, Ursula A Matulonis, Angeles Alvarez Secord, et al.
Pageof 23